Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Outlook Therapeutics® Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics® Participates in Virtual Investor "What This Means" Segment
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.